DR. KATHRYN LOUISE ARENDT M.D.
Prescription History 1639157613
Obstetrics & Gynecology - Gynecology in Kirkland, WA


Quality Rating: 79.16 out of 100 score

NPI Status: Active since January 09, 2006

Contact Information

12815 120TH AVE NE STE E
KIRKLAND, WA
ZIP 98034
Phone: (425) 454-8016
Fax: (425) 453-2827

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. KATHRYN LOUISE ARENDT M.D., an active Gynecology specialist practicing in Kirkland, WA. Our medical registry currently tracks 15 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 619 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 229 claims alone.


Dotti

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 37.6
Days Supply 1,120
WA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply663
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,550.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$159.43

State Avg Cost Per Claim

$104.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 229
30-Day Fills 619.5
Days Supply 18,465
WA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,990
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 748.1% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,942.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$135.12

State Avg Cost Per Claim

$83.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol (Once Weekly)

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 20
30-Day Fills 32.6
Days Supply 952
WA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills23.7
Peer Average Days Supply690
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,397.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.86

State Avg Cost Per Claim

$94.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol (Twice Weekly)

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 25
30-Day Fills 62.8
Days Supply 1,876
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills31.3
Peer Average Days Supply916
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.9% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,564.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$142.58

State Avg Cost Per Claim

$112.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 37
30-Day Fills 110.8
Days Supply 3,324
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,653
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 105.6% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,806.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$535.32

State Avg Cost Per Claim

$549.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 15
30-Day Fills 22.0
Days Supply 372
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply265
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $135.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.04

State Avg Cost Per Claim

$15.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Gemtesa

Generic Formulation: VibegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 63
30-Day Fills 104.0
Days Supply 3,072
WA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills33.7
Peer Average Days Supply993
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 162.5% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,971.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$793.20

State Avg Cost Per Claim

$655.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Imvexxy

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 27.0
Days Supply 764
WA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills17.7
Peer Average Days Supply505
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.5% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,353.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$352.95

State Avg Cost Per Claim

$312.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Methenamine Hippurate

Generic Formulation: Methenamine HippurateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 22
30-Day Fills 52.0
Days Supply 1,560
WA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills41.1
Peer Average Days Supply1,196
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,704.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$168.40

State Avg Cost Per Claim

$96.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Methenamine is used to prevent or control returning urinary tract infections caused by certain bacteria. It is not used to treat an active infection. Antibiotics must be used first to treat and cure the infection. Methenamine is a drug that stops the growth of bacteria in urine. This medication also contains an ingredient that helps to make the urine acidic. When the urine is acidic, methenamine turns into formaldehyde to kill the bacteria. This drug is effective only against bacterial infections in the urinary tract. It will not work for other types of bacterial infections (such as in the blood) or for viral infections (such as the common cold or flu). Unnecessary use or misuse of any antibacterial drug can lead to its decreased effectiveness.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 66
30-Day Fills 114.0
Days Supply 3,420
WA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills55.7
Peer Average Days Supply1,601
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $52,551.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$796.23

State Avg Cost Per Claim

$668.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 288
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.9
Peer Average Days Supply229
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 105.0% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $672.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.41

State Avg Cost Per Claim

$25.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 79
WA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply285
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.62

State Avg Cost Per Claim

$9.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 62
WA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills50.1
Peer Average Days Supply920
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.3% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.52

State Avg Cost Per Claim

$21.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 29.9
Days Supply 898
WA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply932
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,520.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$460.06

State Avg Cost Per Claim

$390.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Progesterone

Generic Formulation: Progesterone, MicronizedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 25
30-Day Fills 55.0
Days Supply 1,650
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills43.7
Peer Average Days Supply1,305
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $975.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.01

State Avg Cost Per Claim

$64.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat infertility in women who do not make enough of a certain natural hormone called progesterone. This hormone is needed to maintain pregnancy. This medication is also used to restore menstrual cycles in women whose cycles have stopped. Progesterone is needed to keep menstrual periods regular.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. KATHRYN LOUISE ARENDT M.D. provides transparency into local medical care patterns within Kirkland, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.